Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Chureeratana Bowonwattanuwong"'
Autor:
Mathus Sawpitiporn, Jiratchaya Sophonphan, Sivaporn Gatechompol, Busarat Karachot, Bancha Chuasuwan, Mariam Duereh, Kiat Ruxrungtham, Isariya Techatanawat, Chutima Manamuti, Akarin Hiransuthikul, Hiv-Nat study team, Anchalee Avihingsanon, Narukjaporn Thammajaruk, Chureeratana Bowonwattanuwong
Publikováno v:
Antiviral therapy. 23(8)
Background Ritonavir (RTV) tablets were not available in Thailand until they were manufactured by the Government Pharmaceutical Organization of Thailand. We assessed pharmacokinetics (PK), safety and efficacy of generic RTV-boosted atazanavir (ATV) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69255fe1b250cad3fe2796963101183a
https://pubmed.ncbi.nlm.nih.gov/30265243
https://pubmed.ncbi.nlm.nih.gov/30265243
Autor:
Chureeratana Bowonwattanuwong, Torsak Bunupuradah, Warangkana Munsakul, Supunnee Jirajariyavej, Kiat Ruxrungtham, Apicha Mahanontharit, Jintanat Ananworanich, Jiratchaya Sophonphan, Virat Klinbuayaem, Bernard Hirschel
Publikováno v:
Antiviral therapy. 19(6)
Background HIV-1 shedding in genital secretions is associated with HIV transmission risk. Limited data exist on the effect of second-line lopinavir/ritonavir mono-therapy (mLPV/r) on genital secretion of HIV RNA. Methods We measured HIV-1 in genital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8657dc9573cf1bc93089c38a2ff690fc
https://pubmed.ncbi.nlm.nih.gov/24464590
https://pubmed.ncbi.nlm.nih.gov/24464590
Autor:
Victor Valcour, Supunnee Jirajariyavej, Ploenchan Chetchotisakd, Virat Klinbuayaem, Warangkana Munsakul, Kiat Ruxrungtham, Wisit Prasithsirikul, Sorakij Bhakeecheep, Chureeratana Bowonwattanuwong, Bernard Hirschel, Apicha Mahanontharit, Jiratchaya Sophonphan, Jintanat Ananworanich, Torsak Bunupuradah
Publikováno v:
Journal of neurovirology. 18(6)
We compared rates of neurocognitive impairment (NCI) among 93 Thai adults failing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based combination antiretroviral therapy (cART) before and after switching to lopinavir/ritonavir monotherapy (mL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30739f7f0cb9ea6df1b6ceb73732ada3
https://pubmed.ncbi.nlm.nih.gov/22993101
https://pubmed.ncbi.nlm.nih.gov/22993101
Autor:
Warangkana Munsakul, Pacharee Kantipong, Ploenchan Chetchotisakd, Sunee Sirivichayakul, Sorakij Bhakeecheep, Kathy Petoumenos, Jintanat Ananworanich, Somnuek Sungkanuparph, Supunnee Jirajariyavej, Virat Klinbuayaem, Wisit Prasithsirikul, Bernard Hirschel, Chureeratana Bowonwattanuwong, Torsak Bunupuradah, Kiat Ruxrungtham
Publikováno v:
Antiviral therapy. 16(7)
Background We studied prevalence of etravirine (ETR) and rilpivirine (RPV) resistance in HIV-1 subtype CRF01_AE infection with first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) failure. Methods A total of 225 adults failing two nucleo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2f375af95990e2c2b9270e254c0029
https://pubmed.ncbi.nlm.nih.gov/22024527
https://pubmed.ncbi.nlm.nih.gov/22024527